{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:53:40Z","timestamp":1791230020691,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T00:00:00Z","timestamp":1402876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T00:00:00Z","timestamp":1402876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2015,4,23]]},"DOI":"10.1038\/onc.2014.164","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T09:10:28Z","timestamp":1402909828000},"page":"2239-2250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":370,"title":["mTORC1 drives HIF-1\u03b1 and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3"],"prefix":"10.1038","volume":"34","author":[{"given":"K M","family":"Dodd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M H","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J R","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A R","family":"Tee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,16]]},"reference":[{"key":"BFonc2014164_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","volume":"33","author":"GL Semenza","year":"2012","unstructured":"Semenza GL . Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33: 207\u2013214.","journal-title":"Trends Pharmacol Sci"},{"key":"BFonc2014164_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cmet.2006.01.012","volume":"3","author":"I Papandreou","year":"2006","unstructured":"Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC . HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006; 3: 187\u2013197.","journal-title":"Cell Metab"},{"key":"BFonc2014164_CR3","doi-asserted-by":"publisher","first-page":"23111","DOI":"10.1074\/jbc.M202487200","volume":"277","author":"H Lu","year":"2002","unstructured":"Lu H, Forbes RA, Verma A . Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 2002; 277: 23111\u201323115.","journal-title":"J Biol Chem"},{"key":"BFonc2014164_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL . Hypoxia\u2014a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38\u201347.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2014164_CR5","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1158\/1078-0432.CCR-10-1360","volume":"16","author":"X Lu","year":"2010","unstructured":"Lu X, Kang Y . Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010; 16: 5928\u20135935.","journal-title":"Clin Cancer Res"},{"key":"BFonc2014164_CR6","doi-asserted-by":"publisher","first-page":"16369","DOI":"10.1073\/pnas.1113483108","volume":"108","author":"CC-L Wong","year":"2011","unstructured":"Wong CC-L, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci USA 2011; 108: 16369\u201316374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2014164_CR7","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1242\/jcs.00385","volume":"116","author":"D Pfander","year":"2003","unstructured":"Pfander D, Cramer T, Schipani E, Johnson RS . HIF-1\u03b1 controls extracellular matrix synthesis by epiphyseal chondrocytes. J Cell Sci 2003; 116: 1819\u20131826.","journal-title":"J Cell Sci"},{"key":"BFonc2014164_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S1535-6108(02)00043-0","volume":"1","author":"K Kondo","year":"2002","unstructured":"Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr . Inhibition of HIF is necessary for tumor suppression by the von Hippel\u2013Lindau protein. Cancer Cell 2002; 1: 237\u2013246.","journal-title":"Cancer Cell"},{"key":"BFonc2014164_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","volume":"8","author":"JS Isaacs","year":"2005","unstructured":"Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung Y-L et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005; 8: 143\u2013153.","journal-title":"Cancer Cell"},{"key":"BFonc2014164_CR10","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/onc.2010.497","volume":"30","author":"RS Preston","year":"2011","unstructured":"Preston RS, Philp A, Claessens T, Gijezen L, Dydensborg AB, Dunlop EA et al. Absence of the Birt\u2013Hogg\u2013Dube gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility. Oncogene 2011; 30: 1159\u20131173.","journal-title":"Oncogene"},{"key":"BFonc2014164_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271\u2013275.","journal-title":"Nature"},{"key":"BFonc2014164_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0955-0674(00)00194-0","volume":"13","author":"GL Semenza","year":"2001","unstructured":"Semenza GL . HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001; 13: 167\u2013171.","journal-title":"Curr Opin Cell Biol"},{"key":"BFonc2014164_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.spen.2006.01.008","volume":"13","author":"T Rosser","year":"2006","unstructured":"Rosser T, Panigrahy A, McClintock W . The diverse clinical manifestations of tuberous sclerosis complex: a review. Semin Pediatr Neurol 2006; 13: 27\u201336.","journal-title":"Semin Pediatr Neurol"},{"key":"BFonc2014164_CR14","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1067\/mjd.2002.120530","volume":"46","author":"JL Arbiser","year":"2002","unstructured":"Arbiser JL, Brat D, Hunter S, D'Armiento J, Henske EP, Arbiser ZK et al. Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J Am Acad Dermatol 2002; 46: 376\u2013380.","journal-title":"J Am Acad Dermatol"},{"key":"BFonc2014164_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.molcel.2012.06.009","volume":"47","author":"C Dibble Christian","year":"2012","unstructured":"Dibble Christian C, Elis W, Menon S, Qin W, Klekota J, Asara John M et al. TBC1D7 is a third subunit of the TSC1\u2013TSC2 complex upstream of mTORC1. Molecular Cell 2012; 47: 535\u2013546.","journal-title":"Molecular Cell"},{"key":"BFonc2014164_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1056\/NEJMc072500","volume":"358","author":"DM Davies","year":"2008","unstructured":"Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008; 358: 200\u2013203.","journal-title":"N Engl J Med"},{"key":"BFonc2014164_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140\u2013151.","journal-title":"N Engl J Med"},{"key":"BFonc2014164_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1158\/1541-7786.MCR-12-0605","volume":"11","author":"Y Guo","year":"2013","unstructured":"Guo Y, Kwiatkowski DJ . Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis. Mol Cancer Res 2013; 11: 467\u2013473.","journal-title":"Mol Cancer Res"},{"key":"BFonc2014164_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1479-5876-8-14","volume":"8","author":"C Woodrum","year":"2010","unstructured":"Woodrum C, Nobil A, Dabora SL . Comparison of three rapamycin dosing schedules in A\/J Tsc2+\/\u2212 mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J Transl Med 2010; 8: 14","journal-title":"J Transl Med"},{"key":"BFonc2014164_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm0202-128","volume":"8","author":"M Guba","year":"2002","unstructured":"Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128\u2013135.","journal-title":"Nat Med"},{"key":"BFonc2014164_CR21","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-06-2757","volume":"13","author":"D Marimpietri","year":"2007","unstructured":"Marimpietri D, Brignole C, Nico B, Pastorino F, Pezzolo A, Piccardi F et al. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin Cancer Res 2007; 13: 3977\u20133988.","journal-title":"Clin Cancer Res"},{"key":"BFonc2014164_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ccr.2006.07.003","volume":"10","author":"TL Phung","year":"2006","unstructured":"Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006; 10: 159\u2013170.","journal-title":"Cancer Cell"},{"key":"BFonc2014164_CR23","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0960-9822(02)00762-5","volume":"12","author":"SS Schalm","year":"2002","unstructured":"Schalm SS, Blenis J . Identification of a conserved motif required for mTOR signaling. Curr Biol 2002; 12: 632\u2013639.","journal-title":"Curr Biol"},{"key":"BFonc2014164_CR24","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ceb.2011.09.003","volume":"23","author":"E Dazert","year":"2011","unstructured":"Dazert E, Hall MN . mTOR signaling in disease. Curr Opin Cell Biol 2011; 23: 744\u2013755.","journal-title":"Curr Opin Cell Biol"},{"key":"BFonc2014164_CR25","doi-asserted-by":"publisher","first-page":"20534","DOI":"10.1074\/jbc.M611782200","volume":"282","author":"SC Land","year":"2007","unstructured":"Land SC, Tee AR . Hypoxia-inducible factor 1 alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007; 282: 20534\u201320543.","journal-title":"J Biol Chem"},{"key":"BFonc2014164_CR26","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","volume":"22","author":"CC Hudson","year":"2002","unstructured":"Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F et al. Regulation of hypoxia-inducible factor 1\u03b1 expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22: 7004\u20137014.","journal-title":"Mol Cell Biol"},{"key":"BFonc2014164_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","volume":"39","author":"K D\u00fcvel","year":"2010","unstructured":"D\u00fcvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010; 39: 171\u2013183.","journal-title":"Mol Cell"},{"key":"BFonc2014164_CR28","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1073\/pnas.1013629108","volume":"108","author":"P Tandon","year":"2011","unstructured":"Tandon P, Gallo CA, Khatri S, Barger JF, Yepiskoposyan H, Plas DR . Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency. Proc Natl Acad Sci USA 2011; 108: 2361\u20132365.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2014164_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1535-6108(03)00187-9","volume":"4","author":"JB Brugarolas","year":"2003","unstructured":"Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr . TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003; 4: 147\u2013158.","journal-title":"Cancer Cell"},{"key":"BFonc2014164_CR30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","volume":"12","author":"GV Thomas","year":"2006","unstructured":"Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12: 122\u2013127.","journal-title":"Nat Med"},{"key":"BFonc2014164_CR31","doi-asserted-by":"publisher","first-page":"27975","DOI":"10.1074\/jbc.M204152200","volume":"277","author":"C Treins","year":"2002","unstructured":"Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E . Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase\/target of rapamycin-dependent signaling pathway. J Biol Chem 2002; 277: 27975\u201327981.","journal-title":"J Biol Chem"},{"key":"BFonc2014164_CR32","doi-asserted-by":"crossref","unstructured":"Yang J, Kalogerou M, Samsel PA, Zhang Y, Griffiths DFR, Gallacher J et al. Renal tumours in a Tsc2+\/\u2212 mouse modeldo not show feedback inhibition of Akt and are effectively prevented by rapamycin. Oncogene 2014.","DOI":"10.1038\/onc.2014.17"},{"key":"BFonc2014164_CR33","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1073\/pnas.0608510104","volume":"104","author":"J Urano","year":"2007","unstructured":"Urano J, Sato T, Matsuo T, Otsubo Y, Yamamoto M, Tamanoi F . Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc Natl Acad Sci USA 2007; 104: 3514\u20133519.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"BFonc2014164_CR34","doi-asserted-by":"publisher","first-page":"E1329","DOI":"10.1152\/ajpendo.00525.2011","volume":"302","author":"KM Dodd","year":"2012","unstructured":"Dodd KM, Tee AR . Leucine and mTORC1\u2014a complex relationship. Am J Physiol\u2014Endocrinol Metab 2012; 302 (11): E1329\u2013E1342.","journal-title":"Am J Physiol\u2014Endocrinol Metab"},{"key":"BFonc2014164_CR35","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.cellsig.2009.02.024","volume":"21","author":"EA Dunlop","year":"2009","unstructured":"Dunlop EA, Dodd KM, Seymour LA, Tee AR . Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein\u00e2\u20ac\u201cprotein interactions for substrate recognition. Cell Signal 2009; 21: 1073\u20131084.","journal-title":"Cell Signal"},{"key":"BFonc2014164_CR36","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1073\/pnas.1013629108","volume":"108","author":"P Tandon","year":"2011","unstructured":"Tandon P, Gallo CA, Khatri S, Barger JF, Yepiskoposyan H, Plas DR . Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency. Proc Natl Acad Sci USA 2011; 108: 2361\u20132365.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2014164_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ccr.2004.06.020","volume":"6","author":"J Brugarolas","year":"2004","unstructured":"Brugarolas J, Kaelin WG Jr . Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 2004; 6: 7\u201310.","journal-title":"Cancer Cell"},{"key":"BFonc2014164_CR38","doi-asserted-by":"publisher","first-page":"e1000038","DOI":"10.1371\/journal.pbio.1000038","volume":"7","author":"ME Feldman","year":"2009","unstructured":"Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009; 7: e1000038.","journal-title":"PLoS Biol"},{"key":"BFonc2014164_CR39","doi-asserted-by":"publisher","first-page":"8023","DOI":"10.1074\/jbc.M900301200","volume":"284","author":"CC Thoreen","year":"2009","unstructured":"Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284: 8023\u20138032.","journal-title":"J Biol Chem"},{"key":"BFonc2014164_CR40","volume-title":"Ku-0063794 is a Specific Inhibitor of the Mammalian Target of Rapamycin (mTOR)","author":"M Garcia","year":"2009","unstructured":"Garcia M, Juan M, Mordan, Jennifer, Clarke, Rosemary G et al. Ku-0063794 is a Specific Inhibitor of the Mammalian Target of Rapamycin (mTOR), Vol. 421. Portland Press: Colchester, 2009."},{"key":"BFonc2014164_CR41","doi-asserted-by":"publisher","first-page":"17414","DOI":"10.1073\/pnas.0809136105","volume":"105","author":"AY Choo","year":"2008","unstructured":"Choo AY, Yoon S-O, Kim SG, Roux PP, Blenis J . Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008; 105: 17414\u201317419.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2014164_CR42","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O'Reilly","year":"2006","unstructured":"O'Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, Smith D et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500\u20131508.","journal-title":"Cancer Res"},{"key":"BFonc2014164_CR43","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cell.2005.10.024","volume":"123","author":"MK Holz","year":"2005","unstructured":"Holz MK, Ballif BA, Gygi SP, Blenis J . mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005; 123: 569\u2013580.","journal-title":"Cell"},{"key":"BFonc2014164_CR44","first-page":"1","volume-title":"The Enzymes","author":"JM Dempsey","year":"2010","unstructured":"Dempsey JM, Mahoney SJ, Blenis J . 1\u2014mTORC1-mediated control of protein translation. In: Fuyuhiko T, Michael NH (eds) The Enzymes, Vol. 28. Academic Press: New York, 2010, pp 1\u201320."},{"key":"BFonc2014164_CR45","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.1038\/sj.onc.1209888","volume":"25","author":"Y Mamane","year":"2006","unstructured":"Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N . mTOR, translation initiation and cancer. Oncogene 2006; 25: 6416\u20136422.","journal-title":"Oncogene"},{"key":"BFonc2014164_CR46","doi-asserted-by":"publisher","first-page":"11101","DOI":"10.1074\/jbc.M413995200","volume":"280","author":"SS Schalm","year":"2005","unstructured":"Schalm SS, Tee AR, Blenis J . Characterization of a conserved C-terminal motif (RSPRR) in ribosomal protein S6 kinase 1 required for its mammalian target of rapamycin-dependent regulation. J Biol Chem 2005; 280: 11101\u201311106.","journal-title":"J Biol Chem"},{"key":"BFonc2014164_CR47","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1042\/BJ20101024","volume":"431","author":"LR Pearce","year":"2010","unstructured":"Pearce LR, Alton GR, Richter DT, Kath JC, Lingardo L, Chapman J et al. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J 2010; 431: 245\u2013255.","journal-title":"Biochem J"},{"key":"BFonc2014164_CR48","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1158\/0008-5472.CAN-05-3090","volume":"66","author":"N Pore","year":"2006","unstructured":"Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A . EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1\u2013independent and HIF-1\u2013dependent mechanisms. Cancer Res 2006; 66: 3197\u20133204.","journal-title":"Cancer Res"},{"key":"BFonc2014164_CR49","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature03205","volume":"433","author":"JD Richter","year":"2005","unstructured":"Richter JD, Sonenberg N . Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005; 433: 477\u2013480.","journal-title":"Nature"},{"key":"BFonc2014164_CR50","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1158\/1541-7786.MCR-07-2177","volume":"6","author":"G Niu","year":"2008","unstructured":"Niu G, Briggs J, Deng J, Ma Y, Lee H, Kortylewski M et al. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1\u03b1 RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res 2008; 6: 1099\u20131105.","journal-title":"Mol Cancer Res"},{"key":"BFonc2014164_CR51","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0960-9822(99)00268-7","volume":"10","author":"K Yokogami","year":"2000","unstructured":"Yokogami K, Wakisaka S, Avruch J, Reeves SA . Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 2000; 10: 47\u201350.","journal-title":"Curr Biol"},{"key":"BFonc2014164_CR52","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0092-8674(95)90311-9","volume":"82","author":"Z Wen","year":"1995","unstructured":"Wen Z, Zhong Z, Darnell JE Jr . Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation. Cell 1995; 82: 241\u2013250.","journal-title":"Cell"},{"key":"BFonc2014164_CR53","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.immuni.2008.08.012","volume":"29","author":"T Weichhart","year":"2008","unstructured":"Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008; 29: 565\u2013577.","journal-title":"Immunity"},{"key":"BFonc2014164_CR54","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1165\/rcmb.2005-0152RC","volume":"33","author":"N El-Hashemite","year":"2005","unstructured":"El-Hashemite N, Kwiatkowski DJ . Interferon-gamma-Jak-Stat signaling in pulmonary lymphangioleiomyomatosis and renal angiomyolipoma: a potential therapeutic target. Am J Resp Cell Mol Biol 2005; 33: 227\u2013230.","journal-title":"Am J Resp Cell Mol Biol"},{"key":"BFonc2014164_CR55","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.cellsig.2009.02.024","volume":"21","author":"EA Dunlop","year":"2009","unstructured":"Dunlop EA, Dodd KM, Seymour LA, Tee AR . Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein\u2013protein interactions for substrate recognition. Cell Signal 2009; 21: 1073\u20131084.","journal-title":"Cell Signal"},{"issue":"6144","key":"BFonc2014164_CR56","doi-asserted-by":"publisher","first-page":"1236566","DOI":"10.1126\/science.1236566","volume":"341","author":"SA Kang","year":"2013","unstructured":"Kang SA, Pacold ME, Cervantes CL, Lim D, Lou HJ, Ottina K et al. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 2013; 341 (6144): 1236566.","journal-title":"Science"},{"key":"BFonc2014164_CR57","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1006\/bbrc.1999.0995","volume":"261","author":"E Minet","year":"1999","unstructured":"Minet E, Ernest I, Michel G, Roland I, Remacle J, Raes M et al. HIF1A gene transcription is dependent on a core promoter sequence encompassing activating and inhibiting sequences located upstream from the transcription initiation site and cis elements located within the 5\u2032UTR. Biochem Biophys Res Commun 1999; 261: 534\u2013540.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2014164_CR58","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1158\/0008-5472.CAN-09-2840","volume":"70","author":"I Barbieri","year":"2010","unstructured":"Barbieri I, Pensa S, Pannellini T, Quaglino E, Maritano D, Demaria M et al. Constitutively active Stat3 enhances Neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res 2010; 70: 2558\u20132567.","journal-title":"Cancer Res"},{"key":"BFonc2014164_CR59","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ccr.2011.03.018","volume":"19","author":"N Li","year":"2011","unstructured":"Li N, Grivennikov Sergei I, Karin M . The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 2011; 19: 429\u2013431.","journal-title":"Cancer Cell"},{"key":"BFonc2014164_CR60","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1158\/0008-5472.CAN-03-3609","volume":"64","author":"N El-Hashemite","year":"2004","unstructured":"El-Hashemite N, Zhang H, Walker V, Hoffmeister KM, Kwiatkowski DJ . Perturbed IFN-\u03b3-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models. Cancer Res 2004; 64: 3436\u20133443.","journal-title":"Cancer Res"},{"key":"BFonc2014164_CR61","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/0008-5472.CAN-09-2468","volume":"70","author":"L Lin","year":"2010","unstructured":"Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 2010; 70: 2445\u20132454.","journal-title":"Cancer Res"},{"key":"BFonc2014164_CR62","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1021\/mp700113r","volume":"4","author":"P Anand","year":"2007","unstructured":"Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB . Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807\u2013818.","journal-title":"Mol Pharm"},{"key":"BFonc2014164_CR63","doi-asserted-by":"publisher","first-page":"29936","DOI":"10.1074\/jbc.M204733200","volume":"277","author":"JS Isaacs","year":"2002","unstructured":"Isaacs JS, Jung Y-J, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM . Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1\u03b1-degradative pathway. J Biol Chem 2002; 277: 29936\u201329944.","journal-title":"J Biol Chem"},{"key":"BFonc2014164_CR64","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1128\/MCB.21.12.3995-4004.2001","volume":"21","author":"E Laughner","year":"2001","unstructured":"Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL . HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995\u20134004.","journal-title":"Mol Cell Biol"},{"key":"BFonc2014164_CR65","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/sj.emboj.7600193","volume":"23","author":"B Raught","year":"2004","unstructured":"Raught B, Peiretti F, Gingras A-C, Livingstone M, Shahbazian D, Mayeur GL et al. Phosphorylation of eukaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J 2004; 23: 1761\u20131769.","journal-title":"EMBO J"},{"key":"BFonc2014164_CR66","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1093\/emboj\/20.16.4370","volume":"20","author":"X Wang","year":"2001","unstructured":"Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG . Regulation of elongation factor 2 kinase by p90RSK1 and p70 S6 kinase. EMBO J 2001; 20: 4370\u20134379.","journal-title":"EMBO J"},{"key":"BFonc2014164_CR67","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2006.01.021","volume":"9","author":"AY Choo","year":"2006","unstructured":"Choo AY, Blenis J . TORgeting oncogene addiction for cancer therapy. Cancer Cell 2006; 9: 77\u201379.","journal-title":"Cancer Cell"},{"key":"BFonc2014164_CR68","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature11083","volume":"485","author":"CC Thoreen","year":"2012","unstructured":"Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM . A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012; 485: 109\u2013113.","journal-title":"Nature"},{"key":"BFonc2014164_CR69","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature10912","volume":"485","author":"AC Hsieh","year":"2012","unstructured":"Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012; 485: 55\u201361.","journal-title":"Nature"},{"key":"BFonc2014164_CR70","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.tibs.2008.08.002","volume":"33","author":"MY Koh","year":"2008","unstructured":"Koh MY, Spivak-Kroizman TR, Powis G . HIF-1 regulation: not so easy come, easy go. Trends Biochem Sci 2008; 33: 526\u2013534.","journal-title":"Trends Biochem Sci"},{"key":"BFonc2014164_CR71","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0014-5793(04)00313-8","volume":"564","author":"AR Tee","year":"2004","unstructured":"Tee AR, Tee JA, Blenis J . Characterizing the interaction of the mammalian eIF4E-related protein 4EHP with 4E-BP1. FEBS Lett 2004; 564: 58\u201362.","journal-title":"FEBS Lett"},{"key":"BFonc2014164_CR72","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/ejhg.2011.38","volume":"19","author":"EA Dunlop","year":"2011","unstructured":"Dunlop EA, Dodd KM, Land SC, Davies PA, Martins N, Stuart H et al. Determining the pathogenicity of patient-derived TSC2 mutations by functional characterization and clinical evidence. Eur J Hum Genet 2011; 19: 789\u2013795.","journal-title":"Eur J Hum Genet"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2014164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2014164","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2014164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T16:03:58Z","timestamp":1647878638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2014164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,16]]},"references-count":72,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2015,4,23]]}},"alternative-id":["BFonc2014164"],"URL":"https:\/\/doi.org\/10.1038\/onc.2014.164","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,16]]},"assertion":[{"value":"13 September 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}